JCO oncology advances · 2026
Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goyal Gaurav, Lurain Kathryn, Lopez Gabby, Rutherford Sarah C, Castellino Sharon, Davison Kelly, Evens Andrew, Smith Sonali M, Kelly Kara, LeBlanc Michael, Song Joo Y, Odeny Thomas, Ratner Lee, Friedberg Jonathan W, Herrera Alex F
Аннотация
PURPOSE: S1826 was an international phase 3 randomized trial that demonstrated improved progression-free survival of nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) over brentuximab vedotin plus AVD (BV+AVD) in newly diagnosed advanced stage classic Hodgkin lymphoma (cHL). Here we report results of enrolled participants with HIV.
PARTICIPANTS AND METHODS: People with HIV (PWH) with a CD4+ T-cell above ≥200 cells/μL and on effective ART with an undetectable HIV viral load within 6 months prior to enrollment were eligible. Participants were randomly assigned in a 1:1 ratio to receive six 28-day cycles of either N+AVD or BV+AVD intravenously. The primary endpoint was progression-free survival.
RESULTS: 16 eligible PWH were enrolled, 11 received N+AVD and 5 received BV+AVD. The median follow-up duration was 32.7 months in the N+AVD arm and 26.7 months in the BV+AVD arm. The 2-year PFS rate was 77.9% in N+AVD arm and 75.0% in the BV+AVD arm. The 2-year OS was 85.7% in the N+AVD arm and 75.0% in the BV+AVD arm. Grade ≥ 3 adverse events were observed in 45% of participants in the N+AVD arm and 50% in the BV+AVD arm with more frequent febrile neutropenia, and severe infections observed in the BV+AVD arm.
CONCLUSIONS: N+AVD is safe and effective in newly diagnosed HIV-associated advanced stage cHL. Clinicaltrials.gov number NCT03907488.
PARTICIPANTS AND METHODS: People with HIV (PWH) with a CD4+ T-cell above ≥200 cells/μL and on effective ART with an undetectable HIV viral load within 6 months prior to enrollment were eligible. Participants were randomly assigned in a 1:1 ratio to receive six 28-day cycles of either N+AVD or BV+AVD intravenously. The primary endpoint was progression-free survival.
RESULTS: 16 eligible PWH were enrolled, 11 received N+AVD and 5 received BV+AVD. The median follow-up duration was 32.7 months in the N+AVD arm and 26.7 months in the BV+AVD arm. The 2-year PFS rate was 77.9% in N+AVD arm and 75.0% in the BV+AVD arm. The 2-year OS was 85.7% in the N+AVD arm and 75.0% in the BV+AVD arm. Grade ≥ 3 adverse events were observed in 45% of participants in the N+AVD arm and 50% in the BV+AVD arm with more frequent febrile neutropenia, and severe infections observed in the BV+AVD arm.
CONCLUSIONS: N+AVD is safe and effective in newly diagnosed HIV-associated advanced stage cHL. Clinicaltrials.gov number NCT03907488.